Brief Introduction

Jiangsu Aidea Pharmaceutical Co., Ltd. (“Aidea Pharma”), set up in Year 2009, is located in Yangzhou, Jiangsu Province and listed on SSE STAR-Market on July 20, 2020.

Aidea Pharma focuses on critical medicine fields with anti-virus, anti-tumor and anti-inflammatory treatment, trying to serve the unmet clinical needs and is committed to exploring, researching and marketing innovative chemical medicines and human-sourced protein products.

In the early days of its establishment, Aidea Pharma successfully developed unique online human urine protein adsorption technology, using highly efficient resin to develop a set of effective process and achieve online and efficient adsorption of urinary proteins like Urinary Trypsin Inhibitor (UTI), Urokinase (UK), and Human Urinary Kallidinogenase (KN). Now Aidea Pharma becomes a large producer and supplier of human-sourced protein products in mainland China.

From 2014, Aidea Pharma has begun to put more concern on developing innovative chemical products.In its current pipeline, there are total 12 products with 6 of them are national class I new drugs,among which four NCE drugs for the treatment of Cancer and AIDS have been approved by CFDA for clinical trials.With the leadership of experienced senior experts and collaboration with high-level talents, Aidea pharma has granted 36 patents and undertaken 3 projects of the 13th “Five-Year Plan” New Drug Research and Development National Major Scientific and Technological Special Projects administered by State Ministry of Science and Technology.

Aidea Pharma has been committed to becoming a respected and excellent pharmaceutical company in China.

Company Overview

Full name Jiangsu Aidea Pharmaceutical Co.,Ltd.
Abbreviations AideaPharma
Code 688488.SH
Founded December 15, 2009
Listing July 20, 2020
Domicile Yangzhou, Jiangsu
STAR Theme Biomedicine
CSRCSector Manufacturing
Has weighted voting rights structure? N/A



  2019 2018 2017
Earnings Per Share 0.09 -- --
R&D expenditure as a % of operating revenue 16.50% 22.35% 30.93%
Operating Revenue 345.23 276.91 136.26
Net Income 33.65 8.62 -37.98

Income Statement (Unit: RMB mn)

  2019 2018 2017
Operating Revenue 345.23 276.91 136.26
Operating Costs 197.30 166.31 95.29
Operating Income 35.20 8.22 -44.68
Pretax Income 38.15 7.54 -44.72
Income Tax 4.50 -1.08 -6.74
Net Income 33.65 8.62 -37.98

Balance Sheet(Unit: RMB mn)

  2019 2018 2017
Current Assets-Total 368.11 310.36 305.07
Non-current Assets-Total 412.87 398.59 354.16
Total Assets 780.98 708.95 659.23
Current Liabilities-Total 209.13 175.11 133.42
Non-current Liabilities-Total 15.62 11.13 11.72
Total Liabilities 224.75 186.24 145.14
Stockholder's Equity
Share Capital 529.71 502.46 502.46
Retained Profits 26.53 20.26 11.64
Total Owners' Equity 556.24 522.72 514.10

Cash Flow Statement (Unit: RMB mn)

  2019 2018 2017
Net Cash Flows-Operating 56.20 -33.50 -67.18
Net Cash Flows-Investing -37.01 -82.50 -56.45
Net Cash Flows-Financing 23.45 37.80 252.90

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
广州维美投资有限公司 94.50 22.50%
维美投资(香港)有限公司 77.69 18.50%
江苏艾迪药业股份有限公司未确认持有人证券专用账户 50.94 12.13%
扬州乐凯企业管理合伙企业(有限合伙) 23.63 5.63%
华泰紫金(江苏)股权投资基金(有限合伙) 15.02 3.58%
江苏毅达并购成长股权投资基金(有限合伙) 14.56 3.47%
傅和祥 13.17 3.13%
江苏高投鑫海创业投资有限公司 12.13 2.89%
杭州双晖投资合伙企业(有限合伙) 9.00 2.14%
苏州观天下投资有限公司 9.00 2.14%
30 Sep 2020

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.